Live Chat

交易 BioNTech BNTX

出售
 买入

BioNTech 实时图表

5m 15m 30m 1h 4h 1d 1w

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%)： 开盘价 高 低

最新新闻

Bitcoin and Trump crypto market trends and impact.
Vanessa L 2025 Jan 24, 11:20

Trump Crypto Analysis and Insights

Cryptocurrencies
Close-up of gold bars on nugget grains, symbolizing metal prices today and commodity gold.
Vanessa L 2025 Jan 24, 10:40

Commodity Gold and Metal Prices Today

Forex Gold Commodities
USD to JPY forecast with currency chart showing forex market trends.
Vanessa L 2025 Jan 24, 10:30

BoJ Interest Rate Hike ; USD to JPY Forecast

Forex JPY USD
A graph showing us stock futures mildly decline after S&P 500 record close.
Vanessa L 2025 Jan 24, 06:30

US Stock Futures Decline After S&P 500 Record Close

Shares Stocks US500
Frances Wang 2025 Jan 23, 16:00

Tesla stock prediction 2025: forecast for the tesla share price

TSLA Stocks Shares
Frances Wang 2025 Jan 23, 16:00

Zuckerberg sold stock: He Sells $2 Billion in Meta Stock Amid AI Push

Stocks
Frances Wang 2025 Jan 23, 16:00

Financial compensation news: Car compensation may affect working people

CFD Trading
Tommy Yap 2025 Jan 23, 16:00

Morning Note: S&P 500 Reaches Record High Amid Trump’s Rate and Oil Policy Hints

Morning Note S&P 500 Oil

信息

点差

1.2197

点差(%)

1.0220 %

杠杆

1:10

隔夜利息（买入）

-0.0597 %

隔夜利息（卖出）

-0.0292 %

币种

USD

交易时间

市场开放

星期五

14:31 - 20:59

星期一

14:31-20:59

星期二

14:31-20:59

星期三

14:31-20:59

星期四

14:31-20:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

29277048832

在外流通股份

239740000

财报日（下一）

0000-00-00

股息收益率

2022-06-17

除息日

2022-06-02

远期年度股息率

0

远期年股息率

0

每股收益

-2.01

详细了解此金融票据

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相关金融票据

资产
出售
买入
更改(%)：

立即交易

立即交易

立即交易

立即交易
相关金融票据
Trustpilot
Live Chat